Cwm LLC Buys 3,681 Shares of Pediatrix Medical Group, Inc. (NYSE:MD)

Cwm LLC lifted its holdings in Pediatrix Medical Group, Inc. (NYSE:MD) by 134.0% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 6,427 shares of the company’s stock after buying an additional 3,681 shares during the period. Cwm LLC’s holdings in Pediatrix Medical Group were worth $74,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. nVerses Capital LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $31,000. Innealta Capital LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $33,000. Nisa Investment Advisors LLC increased its holdings in shares of Pediatrix Medical Group by 47.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,755 shares of the company’s stock worth $36,000 after buying an additional 1,524 shares during the last quarter. Canada Pension Plan Investment Board bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $72,000. Finally, Vanguard Personalized Indexing Management LLC bought a new stake in shares of Pediatrix Medical Group in the 2nd quarter worth about $81,000. 97.71% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Pediatrix Medical Group

In other Pediatrix Medical Group news, CFO C Marc Richards sold 32,562 shares of the business’s stock in a transaction dated Friday, August 9th. The shares were sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the sale, the chief financial officer now directly owns 192,785 shares of the company’s stock, valued at $1,943,272.80. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO C Marc Richards sold 32,562 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The shares were sold at an average price of $10.08, for a total value of $328,224.96. Following the completion of the sale, the chief financial officer now owns 192,785 shares of the company’s stock, valued at approximately $1,943,272.80. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Laura A. Linynsky sold 7,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 27th. The stock was sold at an average price of $11.16, for a total transaction of $78,120.00. Following the completion of the sale, the director now directly owns 30,805 shares of the company’s stock, valued at $343,783.80. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 68,100 shares of company stock valued at $701,889 in the last three months. Company insiders own 2.00% of the company’s stock.

Analyst Upgrades and Downgrades

MD has been the topic of several analyst reports. UBS Group upped their price target on shares of Pediatrix Medical Group from $9.00 to $10.50 and gave the company a “neutral” rating in a report on Friday, August 9th. StockNews.com upgraded shares of Pediatrix Medical Group from a “sell” rating to a “hold” rating in a report on Wednesday, August 7th. Truist Financial upped their price target on shares of Pediatrix Medical Group from $10.00 to $13.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, Jefferies Financial Group upgraded shares of Pediatrix Medical Group from a “hold” rating to a “buy” rating and upped their price target for the company from $8.00 to $14.00 in a report on Thursday, September 26th. Five analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, Pediatrix Medical Group has a consensus rating of “Hold” and an average price target of $10.90.

Pediatrix Medical Group Price Performance

Pediatrix Medical Group stock opened at $12.41 on Friday. The stock has a market cap of $1.07 billion, a price-to-earnings ratio of -4.10, a price-to-earnings-growth ratio of 2.00 and a beta of 1.56. The company has a debt-to-equity ratio of 0.87, a current ratio of 1.38 and a quick ratio of 1.38. Pediatrix Medical Group, Inc. has a 1 year low of $6.62 and a 1 year high of $12.99. The firm has a 50-day moving average of $11.40 and a two-hundred day moving average of $9.27.

Pediatrix Medical Group (NYSE:MD) last released its quarterly earnings data on Tuesday, August 6th. The company reported $0.34 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.31 by $0.03. The company had revenue of $504.30 million during the quarter, compared to analysts’ expectations of $505.49 million. Pediatrix Medical Group had a negative net margin of 12.58% and a positive return on equity of 10.59%. The firm’s quarterly revenue was up .7% on a year-over-year basis. During the same period in the previous year, the company earned $0.37 EPS. On average, research analysts forecast that Pediatrix Medical Group, Inc. will post 1.19 earnings per share for the current year.

Pediatrix Medical Group Company Profile

Pediatrix Medical Group, Inc, together with its subsidiaries, provides newborn, maternal-fetal, pediatric cardiology, and other pediatric subspecialty care services in the United States. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians.